- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07409428
Une étude de phase III sur l'HMPL-760 en association avec R-GemOx contre un placebo en association avec R-GemOx dans le lymphome diffus à grandes cellules B récidivant/réfractaire
Étude randomisée de phase III, en double aveugle, contrôlée positivement, évaluant l'efficacité, la sécurité et la pharmacocinétique de HMPL-760 en association avec R-GemOx par rapport au placebo en association avec R-GemOx chez des patients atteints de lymphome diffus à grandes cellules B (DLBCL) en rechute/réfractaire
This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.
The target population of this study includes patients with DLBCL who are relapsed or refractory.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Dongmei Chen, CPL
- Numéro de téléphone: 86-21-20671794
- E-mail: dongmeic@hutch-med.com
Lieux d'étude
-
-
-
Baoding, Chine
- Recrutement
- Baoding NO.1 Central Hospital
-
Contact:
- Haiying Yao
- Numéro de téléphone: 18617789030
- E-mail: haiyingyaobd@163.com
-
Chercheur principal:
- Haiying Yao
-
Beijing, Chine
- Recrutement
- Beijing GoBroad Hospital
-
Chercheur principal:
- Kai Hu
-
Contact:
- Kai Hu
- Numéro de téléphone: 15010390336
- E-mail: HK13610956245@163.com
-
Beijing, Chine
- Recrutement
- BEIJING TONGREN HOSPITAL, Capital Medical University
-
Chercheur principal:
- Liang Wang
-
Contact:
- Liang Wang
- Numéro de téléphone: 15001108693
- E-mail: wangliangtrhos@126.com
-
Bengbu, Chine
- Recrutement
- The First Affiliated Hospital of Bengbu Medical College
-
Contact:
- Yanli Yang
- Numéro de téléphone: 13855249678
- E-mail: Yangyanli0702@126.com
-
Chercheur principal:
- Yanli Yang
-
Changchun, Chine
- Recrutement
- The First Hospital of Jilin University
-
Chercheur principal:
- Ou Bai
-
Contact:
- Ou Bai
- Numéro de téléphone: 13039046656
- E-mail: lbl2054@163.com
-
Changsha, Chine
- Recrutement
- Hunan Cancer Hospital
-
Chercheur principal:
- Hui Zhou
-
Contact:
- Hui Zhou
- Numéro de téléphone: 13975879796
- E-mail: zhouhui9403@126.com
-
Changsha, Chine
- Recrutement
- The Second Xiangya Hospital of Central South University
-
Chercheur principal:
- Hongling Peng
-
Contact:
- Hongling Peng
- Numéro de téléphone: 18900766137
- E-mail: Penghongling@aliyun.com
-
Changsha, Chine
- Recrutement
- People's Hospital of Hunan Province
-
Contact:
- Can Liu
- Numéro de téléphone: 137 8728 5260
- E-mail: 617170469@qq.com
-
Chercheur principal:
- Can Liu
-
Chengdu, Chine
- Recrutement
- West China Hospital of Sichuan University
-
Chercheur principal:
- Liqun Zou
-
Contact:
- Liqun Zou
- Numéro de téléphone: 18980601027
- E-mail: Clinical_Zou@163.com
-
Chengdu, Chine
- Recrutement
- Sichuan Provincial People's Hospital
-
Contact:
- Xiaobing Huang
- Numéro de téléphone: 18981838236
- E-mail: hxb_trial@163.com
-
Chercheur principal:
- Xiaobing Huang
-
Chongqing, Chine
- Recrutement
- The First Affiliated Hospital of Chongqing Medical University
-
Chercheur principal:
- Xin Wang
-
Contact:
- Xin Wang
- E-mail: 925170788@qq.com
-
Chongqing, Chine
- Recrutement
- Chongqing University Cancer Hospital
-
Chercheur principal:
- Yao Liu
-
Contact:
- Yao Liu
- E-mail: liuyao101709@163.com
-
Fujian, Chine
- Recrutement
- Quanzhou First Hospital.Fujian
-
Contact:
- Xiongpeng Zhu
- Numéro de téléphone: 13805998581
- E-mail: xiongpengzhu@163.com
-
Chercheur principal:
- Xiongpeng Zhu
-
Fuzhou, Chine
- Recrutement
- Fujian Medical University Union Hospital
-
Chercheur principal:
- Jianzhen Shen
-
Contact:
- Jianzhen Shen
- Numéro de téléphone: 138 0955 2722
- E-mail: doctorsjz@163.com
-
Guangzhou, Chine
- Recrutement
- Sun Yat-sen University Cancer Center
-
Chercheur principal:
- Zhiming Li
-
Contact:
- Zhiming Li
- Numéro de téléphone: 13719189172
- E-mail: lzmsysu@163.com
-
Guangzhou, Chine
- Recrutement
- Guangdong Provincial People's Hospital
-
Contact:
- Xiaojuan Wei
- Numéro de téléphone: 86 13560097145
- E-mail: jxw919@hotmail.com
-
Chercheur principal:
- Xiaojuan Wei
-
Guangzhou, Chine
- Recrutement
- ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
-
Chercheur principal:
- Yuhua Li
-
Contact:
- Yuhua Li
- Numéro de téléphone: 13533706656
- E-mail: liyuhua2011gz@163.com
-
Guiyang, Chine
- Recrutement
- The Affiliated Hospital of Guizhou Medical University
-
Chercheur principal:
- Yan Zhang
-
Contact:
- Yan Zhang
- Numéro de téléphone: 86 18984155172
- E-mail: Zhangyan20010802@sina.com
-
Hangzhou, Chine
- Recrutement
- Zhejiang Cancer Hospital
-
Chercheur principal:
- Haiyan Yang
-
Contact:
- Haiyan Yang
- E-mail: 2054451461@qq.com
-
Hangzhou, Chine
- Recrutement
- The First Affiliated Hospital, Zhejiang University
-
Chercheur principal:
- Zhen Cai
-
Contact:
- Zhen Cai
- Numéro de téléphone: 13857190311
- E-mail: czclinicaltrial@163.com
-
Harbin, Chine
- Recrutement
- Harbin Medical University Cancer Hospital
-
Contact:
- Qingyuan Zhang
- Numéro de téléphone: 13313612989
- E-mail: sy86298276@163.com
-
Chercheur principal:
- Qingyuan Zhang
-
Hefei, Chine
- Recrutement
- The Second Affiliated Hospital of Anhui Medical University
-
Contact:
- Zhimin Zhai
- Numéro de téléphone: 13855147434
- E-mail: zzzm889@163.com
-
Chercheur principal:
- Zhimin Zhai
-
Jinan, Chine
- Recrutement
- Qilu Hospital of Shandong University
-
Contact:
- Shuqian Xu
- Numéro de téléphone: 18560087013
- E-mail: yoyoshuqian@126.com
-
Chercheur principal:
- Shuqian Xu
-
Jinan, Chine
- Recrutement
- Shandong Cancer Hospital & Institute
-
Chercheur principal:
- Zengjun Li
-
Contact:
- Zengjun Li
- Numéro de téléphone: 15735178591
- E-mail: zengjunli@163.com
-
Kunming, Chine
- Pas encore de recrutement
- The First Affiliated Hospital of Kunming Medical University
-
Contact:
- Mingxia Shi
- Numéro de téléphone: 86 138 8806 0581
- E-mail: shmxia2002@sina.com
-
Chercheur principal:
- Mingxia Shi
-
Nanchang, Chine
- Recrutement
- Jiangxi Cancer Hospital
-
Chercheur principal:
- Yan Huang
-
Contact:
- Yan Huang
- E-mail: 29265061@qq.com
-
Nanjing, Chine
- Recrutement
- Jiangsu Cancer Hospital
-
Chercheur principal:
- Yan Zhang
-
Contact:
- Yan Zhang
- Numéro de téléphone: 13914712395
- E-mail: zhangyan1106@njmu.edu.cn
-
Nanjing, Chine
- Recrutement
- Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
-
Contact:
- Jingyan Xu
- Numéro de téléphone: 86 13951969610
- E-mail: xjy1967@sina.com
-
Chercheur principal:
- Jingyan Xu
-
Nanning, Chine
- Recrutement
- The First Affiliated Hospital of Guangxi Medical University
-
Chercheur principal:
- Zhigang Peng
-
Contact:
- Zhigang Peng
- E-mail: 2557382235@qq.com
-
Qingdao, Chine
- Recrutement
- The Affiliated Hospital of Qingdao University
-
Contact:
- Xia Zhao
- Numéro de téléphone: 18661803088
- E-mail: Zhaoxia@qdu.edu.cn
-
Chercheur principal:
- Xia Zhao
-
Shanghai, Chine
- Recrutement
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
-
Chercheur principal:
- Weili Zhao
-
Contact:
- Weili Zhao
- Numéro de téléphone: 86 13512112076
- E-mail: zwl_trial@163.com
-
Shanghai, Chine
- Recrutement
- Tongji Hospital of Tongji University
-
Contact:
- Ping Li
- Numéro de téléphone: 13564181131
- E-mail: lilyforever76@126.com
-
Chercheur principal:
- Ping Li
-
Shanghai, Chine
- Pas encore de recrutement
- Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
-
Chercheur principal:
- Ligen Liu
-
Contact:
- Ligen Liu
- Numéro de téléphone: 86 18017337037
- E-mail: llg3532@shtrhospital.com
-
Shenyang, Chine
- Recrutement
- Shengjing Hospital of China Medical University
-
Chercheur principal:
- Wei Yang
-
Contact:
- Wei Yang
- Numéro de téléphone: 18940251012
- E-mail: sjyangw@163.com
-
Shenzhen, Chine
- Recrutement
- Shenzhen people's hospital
-
Chercheur principal:
- Jihao Zhou
-
Contact:
- Jihao Zhou
- Numéro de téléphone: 86 18718678693
- E-mail: zhoujihao@aliyun.com
-
Taiyuan, Chine
- Recrutement
- Shanxi Provincial Cancer Hospital
-
Chercheur principal:
- Liping Su
-
Contact:
- Liping Su
- Numéro de téléphone: 13835158122
- E-mail: slpsy2022@163.com
-
Tangshan, Chine
- Recrutement
- North China University of Science and Technology Affiliated Hospital
-
Contact:
- Zhenyu Yan
- Numéro de téléphone: 15931508262
- E-mail: hbyzy2011@163.com
-
Chercheur principal:
- Zhenyu Yan
-
Tianjin, Chine
- Recrutement
- Tianjin Medical University Cancer Institute & Hospital
-
Chercheur principal:
- Zhengzi Qian
-
Contact:
- Zhengzi Qian
- Numéro de téléphone: 13702031222
- E-mail: qzz@163.com
-
Tianjin, Chine
- Recrutement
- Tianjin People's Hospital
-
Contact:
- Xingli Zhao
- Numéro de téléphone: 13752255454
- E-mail: insectzhao@163.com
-
Chercheur principal:
- Xingli Zhao
-
Tianjin, Chine
- Recrutement
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
-
Chercheur principal:
- Dehui Zou
-
Contact:
- Dehui Zou
- Numéro de téléphone: 13602100955
- E-mail: zoudehui@ihcams.ac.cn
-
Wenzhou, Chine
- Recrutement
- The First Affiliated Hospital of WMU
-
Contact:
- Songfu Jiang
- Numéro de téléphone: 86 15305770033
- E-mail: jiangsongfu@189.cn
-
Chercheur principal:
- Songfu Jiang
-
Wuhan, Chine
- Recrutement
- Hubei Cancer Hospital
-
Chercheur principal:
- Huijing Wu
-
Contact:
- Huijing Wu
- E-mail: 3269614878@qq.com
-
Wuhan, Chine
- Recrutement
- Wuhan Union Hospital of China
-
Chercheur principal:
- Liling Zhang
-
Contact:
- Liling Zhang
- Numéro de téléphone: 15871725926
- E-mail: lily1228@sina.com
-
Xi'an, Chine
- Recrutement
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Chercheur principal:
- Pengcheng He
-
Contact:
- Pengcheng He
- Numéro de téléphone: 18991232609
- E-mail: hepc_gcp@163.com
-
Xi'an, Chine
- Recrutement
- The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
-
Chercheur principal:
- Jie Liu
-
Contact:
- Jie Liu
- Numéro de téléphone: 86 18092662371
- E-mail: lieujie@163.com
-
Xiamen, Chine
- Pas encore de recrutement
- The First Affiliated Hospital of Xiamen University
-
Chercheur principal:
- Bing Xu
-
Contact:
- Bing Xu
- Numéro de téléphone: 86 18750918842
- E-mail: xubingzhangjian@126.com
-
Xuzhou, Chine
- Recrutement
- The Affiliated Hospital of Xuzhou Medical University
-
Contact:
- Wei Sang
- Numéro de téléphone: 86 13645207648
- E-mail: 13645207648@126.com
-
Chercheur principal:
- Wei Sang
-
Zhengzhou, Chine
- Recrutement
- Henan Cancer Hospital
-
Chercheur principal:
- Keshu Zhou
-
Contact:
- Keshu Zhou
- Numéro de téléphone: 13674902391
- E-mail: dr_zkshu23810@163.com
-
Zhengzhou, Chine
- Recrutement
- The First Affiliated Hospital of Zhengzhou University
-
Contact:
- Xudong Zhang
- Numéro de téléphone: 13633825183
- E-mail: feverxxd@126.com
-
Chercheur principal:
- Xudong Zhang
-
Ürümqi, Chine
- Recrutement
- People's Hospital of Xinjiang Uygur Autonomous Region
-
Chercheur principal:
- Yan Li
-
Contact:
- Yan Li
- Numéro de téléphone: 86 13639935315
- E-mail: liyan232917@139.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine
- Recrutement
- Fudan University Shanghai Cancer Center
-
Contact:
- Fangfang Lv
- Numéro de téléphone: 18017312613
- E-mail: Lvff80@163.com
-
Chercheur principal:
- Fangfang Lv
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Sign the ICF and be able to follow the requirements of study protocol;
- Age ≥18 years;
- ECOG performance status score between 0 and 2;
- Histopathologically confirmed diagnosis of DLBCL;
- The investigator judges that the patient's current condition requires further treatment;
- Patients should have at least one bi-dimensionally measurable lesion;
- Expected survival is more than 12 weeks;
Exclusion Criteria:
- Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
- Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
- Organ insufficiency;
- Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
- History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
- Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
- The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
- Clinically significant active infection;
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: The experimental group
Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle. |
Patients will receive HMPL-760 once daily (QD) orally. R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Autres noms:
|
|
Comparateur placebo: The control group
Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group. |
R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Autres noms:
Patients will receive HMPL-760 placebo once daily (QD) orally. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression-free survival (PFS)
Délai: Up to approximately two years
|
Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first. |
Up to approximately two years
|
|
End of treatment (EOT)
Délai: Up to approximately two years
|
Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy). |
Up to approximately two years
|
|
Systemic antitumor therapy
Délai: Up to approximately two years
|
Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy). |
Up to approximately two years
|
|
Overall survival (OS)
Délai: Up to approximately two years
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately two years
|
|
systematic anti-tumor therapy
Délai: Up to approximately two years
|
OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
|
Premature withdrawal from study treatment
Délai: Up to approximately two years
|
OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Independent review committee (IRC)-assessed PFS
Délai: Up to approximately two years
|
Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). |
Up to approximately two years
|
|
IRC- and investigator-assessed objective response rate (ORR)
Délai: Up to approximately two years
|
Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR) |
Up to approximately two years
|
|
IRC- and investigator-assessed complete response rate (CRR)
Délai: Up to approximately two years
|
Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR) |
Up to approximately two years
|
|
IRC- and investigator-assessed duration of response (DoR)
Délai: Up to approximately two years
|
For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first |
Up to approximately two years
|
|
IRC- and investigator-assessed clinical benefit rate (CBR)
Délai: Up to approximately two years
|
Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD) |
Up to approximately two years
|
|
IRC- and investigator-assessed time to response (TTR)
Délai: Up to approximately two years
|
Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR) |
Up to approximately two years
|
|
Safety Endpoints
Délai: Up to approximately two years
|
|
Up to approximately two years
|
|
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Délai: At the end of Cycle 4 (each cycle is 21 days)]
|
including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. |
At the end of Cycle 4 (each cycle is 21 days)]
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Biomarker assessment
Délai: Up to approximately two years
|
Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy. |
Up to approximately two years
|
|
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Délai: Up to approximately two years
|
Human metabolites of HMPL-760 when co-administered with R-GemOx |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Délai: Up to approximately two years
|
maximum concentration in steady-state (Cmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Délai: Up to approximately two years
|
time to maximum concentration in steady-state (Tmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Délai: Up to approximately two years
|
Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Délai: Up to approximately two years
|
The rate at which the drug is eliminated from the body (CL/F) (if applicable ) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Délai: Up to approximately two years
|
The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable) |
Up to approximately two years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Weili Zhao, Ruijin Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Lymphome non hodgkinien
- Lymphome à cellules B
- Lymphome
- Maladies hémiques et lymphatiques
- Lymphome diffus à grandes cellules B
- Acides aminés, peptides et protéines
- Protéines
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Thérapeutique
- Voies d'administration du médicament
- Pharmacothérapie
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Complexes de coordination
- Désoxycytidine
- Cytidine
- Nucléosides pyrimidine
- Pyrimidines
- Anticorps, monoclonal et murin
- Oxaliplatine
- Rituximab
- Gemcitabine
- Injections
Autres numéros d'identification d'étude
- 2025-760-00CH1
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .